Gilead Sciences, Inc. (GILD)
$
151.81
-3.99 (-2.63%)
Key metrics
Financial statements
Free cash flow per share
7.7778
Market cap
188.3 Billion
Price to sales ratio
6.3972
Debt to equity
0
Current ratio
1.6834
Income quality
0.6752
Average inventory
3.1 Billion
ROE
0.4101
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Gilead Sciences, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines addressing unmet medical needs in the United States, Europe, and internationally. The company has achieved a significant net income of $8,510,000,000.00 showcasing its strong financial health. The diluted EPS is $6.78 accounting for potential share dilution, which is an important metric for investors. Furthermore, the net income ratio stands at 0.29 reflecting the company's profitability margin effectively. Gilead's EBITDA is $10,820,000,000.00 serving as a key indicator of its operational profitability. Additionally, the gross profit ratio of 0.87 reflects the efficiency of the company's production and sales operations. The product portfolio includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla for HIV/AIDS treatment, as well as Veklury for COVID-19. Gilead also offers therapies for liver diseases, hematology, oncology, and related cell therapies. The company's collaborations with notable partners such as Arcus Biosciences, Pionyr Immunotherapeutics, and Bristol-Myers Squibb exemplify its strategic approach to innovation. Incorporated in 1987, Gilead is headquartered in Foster City, California. The stock is reasonably priced at $114.09 appealing to a broad range of investors. With a large market capitalization of $188,347,630,800.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its category. Moreover, the stock has a high average trading volume of 7,376,476.00 indicating strong liquidity, which is an essential factor for investors seeking reliable investments. By fulfilling unmet medical needs and maintaining strong financial metrics, Gilead Sciences continues to be a vital entity in its field, dedicated to providing effective solutions for serious health conditions while upholding a commitment to improvement and advancement in biopharmaceutical science.
Is Gilead Sciences, Inc. (GILD) a good investment?
Investing in Gilead Sciences, Inc. (GILD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Gilead Sciences, Inc. (GILD)'s stock forecast?
Analysts predict Gilead Sciences, Inc. stock to fluctuate between $93.37 (low) and $157.29 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Gilead Sciences, Inc.'s market capitalization?
As of 2026-02-12, Gilead Sciences, Inc.'s market cap is $188,347,630,800, based on 1,240,680,000 outstanding shares.
How does Gilead Sciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Gilead Sciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Gilead Sciences, Inc. pay dividends?
Gilead Sciences, Inc. pays dividends. The current dividend yield is 2.10%, with a payout of $0.82 per share.
How can I buy Gilead Sciences, Inc. (GILD) stock?
To buy Gilead Sciences, Inc. (GILD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GILD. Place an order (Market, Limit, etc.).
What is the best time to invest in Gilead Sciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Gilead Sciences, Inc. stock ever split?
Gilead Sciences, Inc.'s last stock split was 2:1 on 2013-01-28.
How did Gilead Sciences, Inc. perform in the last earnings report?
Revenue: $29,443,000,000 | EPS: $6.84 | Growth: 1,700%.
Where can I find Gilead Sciences, Inc.'s investor relations reports?
Visit https://www.gilead.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Gilead Sciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Gilead Sciences, Inc. stock?
All-time high: $157.29 (2026-02-11) | All-time low: $57.17 (2022-06-14).
What are the key trends affecting Gilead Sciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.
zacks.com
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
schaeffersresearch.com
Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.
seekingalpha.com
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
zacks.com
While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Gilead Sciences (GILD) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.9 per share a year ago.
wsj.com
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
seekingalpha.com
I rate Gilead Sciences (GILD) a 'Buy' with a $191 price target. It offers an attractive 2.1% dividend yield and low volatility. GILD's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk versus peers. Strong profitability, efficient capital allocation, and robust dividend growth capacity underpin GILD's investment case for safety and income.
defenseworld.net
a16z Perennial Management L.P. bought a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,614 shares of the biopharmaceutical company's stock, valued at approximately $401,000. Other institutional investors and hedge funds
businesswire.com
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therap.
See all news
